Novogene filed its lawsuit late Tuesday in the U.S. District Court in Washington to formally challenge the Pentagon. The Defense Department had placed the firm on its Chinese military companies list back in June, prohibiting direct agency contracts. Other major corporations added to the list during that same period include Alibaba, Baidu, BYD, and NIO. Novogene now joins multiple Chinese enterprises that have brought legal action against the Pentagon over these blacklist designations.
Key points
Direct contracting between the Defense Department and Novogene is currently prohibited be…: Direct contracting between the Defense Department and Novogene is currently prohibited because of the military designation.
The company is actively pursuing federal litigation to overturn the claim that it aids Be…: The company is actively pursuing federal litigation to overturn the claim that it aids Beijing's military.
Several other Chinese corporations have launched similar lawsuits against the Pentagon to…: Several other Chinese corporations have launched similar lawsuits against the Pentagon to challenge their inclusion on the list.
Sources checked by our analysis pipeline: 1
Nov 4 : Chinese genetic sequencing firm Novogene sued the Pentagon late Tuesday in U.S. District Court in Washington over its inclusion on a US list of companies allegedly aiding Beijing's military.
In June, the Defense Department added Novogene, Chinese e-commerce giant Alibaba internet search provider Baidu and automakers BYD and NIO and others to its list of "Chinese military companies" that prohibits the Defense Department from contracting directly with the firms.
A number of Chinese firms have sued the Pentagon over the designations.
The connected television software company relies on advertising and free ad-supported streaming television partnerships to generate revenue across living room displays. With rapid expansion driving a substantially larger consumer base year over year, the firm is strengthening its balance sheet through blended financing. This capital injection positions the business to support its widening reach in the competitive smart television landscape.
Global media giant NBCUniversal and venture firm Hornbill have joined forces to back the parent entity of the Story TV platform. The substantial capital infusion positions the digital entertainment venture to scale its footprint in the regional microdrama market. This financial milestone reflects growing investor confidence in bite-sized streaming formats.
The corporate division creates two distinct publicly traded entities that dismantle decades of aggressive healthcare consolidation while preserving the well-known CVS branding across both organizations. This dramatic shift isolates the retail drugstore network from the massive insurance, pharmacy benefits, and clinical services operations. However, retaining the high-cost specialty pharmacy within the payer business maintains a contentious alignment that has drawn intense scrutiny over healthcare profits.